ABOUT US

Based on innovative scientific achievements,
Pimedbio's first-in-class drugs
  • home
  • About Us
  • Leadership

Leadership

Seonggu Ro

Ph.D.

신약 R&D 관련 경력
CrystalGenomics, Inc. (Principal Scientist, Drug Design & Informatics)(CTO, 2000 - 2017)
LG Life Science (Scientist, Drug Design & Informatics, 1994 - 2000)
Univ. of California at San Diego (Post-doc, Structural Studies & Drug Design, 1991-1994)
Univ. of California at San Diego (Ph.D., Medicinal & Peptidomimetic Chemistry, 1987-1991)
주요 신약 R&D 과제
Next-generation NSAIDs: Approved in Korea and on the market
Antibiotics for superbugs: Phase 2 clinical stage
Targeted cancer therapeutics: Phase 1b/2 clinical stage (2 indications)
Early-stage drug discovery & licensing: 2 candidates out-licensed
Global pharma collaborations: AstraZeneca, Daiichi Sankyo, etc.
신약 R&D 경험
Drug design & medicinal chemistry: Small molecules, peptidomimetics, peptides
Innovative drug discovery: First-in-class & best-in-class candidates
Drug development & commercialization: Non-clinical, clinical, approval, pricing, marketing

Donggyu Shin

Ph.D.

신약 R&D 관련 경력
Korea Drug Development Fund (Senior Researcher, 2016 - 2017)
Samsung Advanced Institute of Technology (Research Staff Member, 2012 - 2015)
KAIST (Ph.D., Drug Design & Informatics, 2003 - 2008)
CrystalGenomics, Inc. (Principal Scientist, Drug Design & Informatics, 2000 - 2012)
LG Life Science (Scientist, Drug Design & Informatics, 1998-2000)
주요 신약 R&D 과제
Small molecule drug design: Superbug antibiotics (Phase 2), targeted cancer drugs (Phase 1b/2), hypoxia therapy (U.S. out-licensed)
Peptide & antibody drug design
Global pharma collaborations
신약 R&D 경험
Big data analysis: Genomics, proteomics, chemical space
Drug design: Small molecules, peptides, proteins
Drug discovery: First-in-class & best-in-class candidates